Cited by 104Virus-based gene therapy researchHemophilia Treatment and ResearchRNA Interference and Gene Delivery

Adeno‐associated virus vectors and hematology

Open access
Russell, David W., Kay, Mark A.·1999·Blood

Abstract

Gene therapists have a special fondness for hematology. Initially, this was due to the many inherited diseases that could potentially be cured by ex vivo genetic modification of hematopoietic stem cells. Once the early murine leukemia virus (MLV) vectors were found to transduce only a small percentage of primate stem cells, the search began for other types of vectors that might work more efficiently, and adeno-associated virus (AAV) vectors were among the first alternatives to be investigated. Although a substantial amount of work with AAV vectors has occurred over the last several years, the bulk of evidence suggests that they transduce hematopoietic stem cells poorly, and that they will not replace retroviral vectors in stem cell gene transfer applications. Instead, it is applications involving the production of secreted proteins that now appear especially promising for AAV vectors, where they are delivered by direct injection rather than ex vivo cell manipulation. Recent animal studies have shown that AAV vectors encoding factor IX can lead to long-term, therapeutic clotting factor levels after in vivo administration, setting the stage for what may well be a cure for hemophilia B in the near future. Animal experiments have also shown that AAV vectors expressing erythropoietin can produce dramatic increases in hematocrit levels. Here we will review the role of AAV vectors in the field of hematology, including the basic biology of AAV, vector transduction properties, their use in hematopoietic cells, and their potential for delivering secreted proteins such as clotting factors and cytokines.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.v94.3.864.415k34_864_874

Cites

131 of 132 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

5 of the 137 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Russell, D. W., & Kay, M. A.
Affiliations
University of Washington (US)
Venue
Blood
Published
1999-08-01
Volume
94
Issue
3
Pages
864-874
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W1519039806
Cited by
104
References
137
Citations by year
2026: 1 · 2024: 1 · 2023: 3 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 4 · 2012: 4
FWCI
6.18
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute (P01HL053750, HL 53682, HL53750, R01HL053682)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK055759)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
adeno-associated virus vectors, hematopoietic stem cells, gene therapy, retroviral vectors, factor IX, hemophilia B, erythropoietin, hematocrit, secreted proteins, cytokines, coagulation factors
MeSH terms
Dependovirus, Animals, Genetic Vectors, Hematologic Diseases, Humans, Genetic Therapy, Gene Transfer Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review